Sector News

Britain’s AstraZeneca launches $1 billion China investment fund with CICC

November 6, 2019
Life sciences

AstraZeneca said it is launching a new fund with China International Capital Corporation (CICC) to invest $1 billion in China’s healthcare sector, as it expands its research work in the country.

The fund would look to invest in Chinese firms, with companies in a life-sciences park it helped open in the eastern city of Wuxi last year to be among its first beneficiaries, the British drugmaker’s chief executive officer, Pascal Soriot, told Reuters.

AstraZeneca was a minority partner in the fund and would mainly play an advisory role in selecting investments and supporting the firms, he said. The companies did not disclose financial details of the deal.

“It’s a substantial investment on our side, but also our financial partners,” Soriot said of the agreement, to be signed with the Chinese investment bank CICC on the sidelines of the China International Import Expo on Wednesday.

“We can help choose some of those investments but we can also help along the way the startup companies, develop products and find their way around the world” he said, describing it as AstraZeneca’s largest-scale healthcare industrial fund.

The company also planned to expand an existing research and development center in Shanghai from 450 employees to 1,000, and establish a new artificial intelligence innovation center in the city.

Western drugmakers have profited from partnerships in China, where AstraZeneca’s sales have doubled since 2012, as well as a softening in the regulatory environment for pharmaceutical firms.

But the government has also been trying to slash drug prices, changing the playing field as many firms had relied in the past on selling older drugs at premium prices. In September, China also expanded a pilot bulk-buying program to the entire country in an attempt to negotiate lower prices from drug manufacturers.

Soirot said these were both factors in AstraZeneca’s decision to make those investments in China, as the price pressures were encouraging companies to create new drugs that the government was approving and reimbursing at a faster pace.

AstraZeneca, he said, wanted to start making drugs it could export globally from China. Areas of opportunity included oncology and respiratory diseases.

“Historically, until today, our Chinese team has been developing global products for the Chinese market. We want now the Chinese team to take the global leadership on some projects,” he said.

By Brenda Goh

Source: Reuters

Related News

January 16, 2020

WuXi Bio buys Germany-based manufacturing plant from Bayer

Life sciences

LinkedIn Twitter FacebookShanghai, China-based Wuxi Biologics inked a deal with Germany’s Bayer to take over the operations of Bayer’s drug manufacturing factory in Leverkusen, Germany. It is also buying the […]

January 16, 2020

How will Amgen make its $13.4B Otezla buy pay off? New launches, for one, CEO says

Life sciences

LinkedIn Twitter FacebookWhen Amgen shelled out $13.4 billion late last year to pick up Celgene’s blockbuster immunology med Otezla, it made a calculated guess the drug had some untapped fuel […]

January 15, 2020

JPM: Want clues into Gilead’s M&A strategy? Check out last year’s Galapagos deal

Life sciences

LinkedIn Twitter FacebookAfter taking the reins at Gilead early last year, CEO Daniel O’Day’s been heading up the company long enough to understand what investors really want: more transparency and […]